Sheet 1 of 1

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

t 1 of 1				
Application Number	10/616,692			
Filing Date	July 9, 2003			
First Named Inventor	Nelson et al.			
Art Unit	1614			
Examiner Name	Royds, Leslie A			

Attorney Docket Number 47-00B

Confirmation No. 1639 GWS 1/2/2009

U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No.1	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No.1	Foreign Patent Document Number (include WiPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²
	1	DE 44 28 199 A1	02/15/1996	UNIV LUDWIGS ALBERT [DE]		

NON-PATENT LITERATURE DOCUMENTS

	NON-I ATEN ETERATORE DOCUMENTO					
Examiner Initial*			T 2			
Benazzi, F. (1997), "Parkinson's Disease Worsened by Nefazodone," International Journal of Geriatric Psychiatry, John Wiley and Sons, Chiches GB, Vol. 1, No. 12, 1 December 1997, pg. 1195		International Journal of Geriatric Psychiatry, John Wiley and Sons, Chichester,				
Hauser, R. A. et al. (1997), "Sertraline for the Treatment of Depression in Parkinson's Disease," Movement Disorders, Raven Press, New York, NY, Vol. 12, No. 5, pp. 756-759		Parkinson's Disease," Movement Disorders, Raven Press, New York, NY, US,				
Korpelainen, J.T. et al. (1998), "Moelobemide-Induced Hypersexuality in Patients with Stroke and Parkinson's Disease," Clinical Neuropharmacolog Raven Press, New York, NY, US, Vol. 21, No. 4, pp. 251-254 Simons, J. A. (1996), "Fluoxetine in Parkinson's Disease," Movement Disorders, Raven Press, New York, NY, US, Vol. 11, No. 5, p. 581/582 Supplementary European Search Report dated October 1, 2008 for corresponding European Patent Application No. 03763398.9		Patients with Stroke and Parkinson's Disease," Clinical Neuropharmacology,				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.